Repligen Initiates Phase 1 Clinical Trial of RG2833 in Patients with Friedreich's Ataxia

WALTHAM, MA - March 15, 2012 - Repligen Corporation (NASDAQ:RGEN) announced today that it has enrolled its first patient in a Phase 1 clinical trial of RG2833 in adult patients with Friedreich's ataxia (FA). read more .....